Serina Therapeutics, Inc.SERNYSE
LOADING
|||
Cash Flow Under Pressure
Trending lower, below historical average, modest growth trend.
Left:
||||
Operating cash flow minus capital expenditures
Latest
$-17.16M
↓ 128% below average
Average (8y)
$-7.54M
Historical baseline
Range
High:$-2.09M
Low:$-17.16M
CAGR
+9.3%
Consistent expansion
| Period | Value | Change |
|---|---|---|
| 2024 | $-17.16M | -475.8% |
| 2023 | $-2.98M | -42.9% |
| 2022 | $-2.09M | +11.6% |
| 2021 | $-2.36M | +69.9% |
| 2020 | $-7.84M | +27.4% |
| 2019 | $-10.80M | -9.2% |
| 2018 | $-9.89M | -57.3% |
| 2017 | $-6.29M | +25.6% |
| 2016 | $-8.45M | - |